Cadenza Bio

Life Sciences

Cadenza Bio is dedicated to breaking the cycle of MS, leading to transformative changes in patient lives. This goal extends beyond symptom relief; they strive to halt the progression of disease and return high quality of life to patients.

Why we invested:


Market Need

Current approved drugs for MS focus on dampening the immune attack to reduce disease recurrence. They don’t prevent deterioration of the nerves or repair ongoing damage; that is what Cadenza Bio is passionately committed to doing.


Superior Technology

Cadenza Bio was founded to accelerate and support the development of a series of novel, non-steroidal, highly selective compounds targeting Estrogen Receptor â (ERâ). Its patented and patent-pending compounds have shown therapeutic efficacy in preclinical animal models of MS and Endometriosis.


Founders & Team

Founder/CEO Carol Curtis, PhD has strong expertise in company building, early-stage venture capital, managing operations and R&D, and interacting with FDA. Founder/COO Elaine Hamm, PhD has extensive experience in drug development and technology transfer and has successfully exited two portfolio companies.

  • "We could not be more pleased to have Boyd Street Ventures as an investor. Their management team and Strategic Advisory Board can be a great source of insight, particularly in the areas of strategy and operations, and they are actively engaged in the honing for success."

  • "James has been extremely helpful in making important introductions for us. I appreciate the fact that he’s always asking me about our plans to grow even faster, and it seems that every time I talk to him he has another great idea for a potential new customer."

  • "BSV is not just a name on our company cap table. They are a valuable business partner as an investor offering strategic guidance and a strong network of industry connections, all of which contribute to our enhanced growth and success."

Question? Just schedule a call with the BSV team.